Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Y5ED
|
|||
Former ID |
DIB015617
|
|||
Drug Name |
AV-203
|
|||
Synonyms |
ErbB3-targeted antibodies (cancer), AVEO/Biogen Idec
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Aveo oncology
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Erbb3 tyrosine kinase receptor (Erbb-3) | Target Info | . | [2] |
KEGG Pathway | ErbB signaling pathway | |||
Calcium signaling pathway | ||||
Endocytosis | ||||
Proteoglycans in cancer | ||||
MicroRNAs in cancer | ||||
NetPath Pathway | TNFalpha Signaling Pathway | |||
Panther Pathway | Cadherin signaling pathway | |||
EGF receptor signaling pathway | ||||
Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
ErbB receptor signaling network | ||||
a6b1 and a6b4 Integrin signaling | ||||
WikiPathways | ErbB Signaling Pathway | |||
Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
Signaling Pathways in Glioblastoma | ||||
miR-targeted genes in muscle cell - TarBase | ||||
Heart Development |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01603979) A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.